craft-sa-dev Home  

PMC:1283364 / 4723-4979 JSONTXT 4 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1190 1-3 IN denotes in
T1191 4-12 NNS denotes patients
T1192 12-13 . denotes .
T1193 13-116 sentence denotes However, the chemical secretase inhibitors most likely to reach human trials are still in development.
T1194 14-21 RB denotes However
T1196 21-23 , denotes ,
T1197 23-26 DT denotes the
T1199 27-35 JJ denotes chemical
T1200 36-45 NN denotes secretase
T1198 46-56 NNS denotes inhibitors
T1201 57-61 RBS denotes most
T1202 62-68 JJ denotes likely
T1203 69-71 TO denotes to
T1204 72-77 VB denotes reach
T1205 78-83 JJ denotes human
T1206 84-90 NNS denotes trials
T1195 91-94 VBP denotes are
T1207 95-100 RB denotes still
T1208 101-103 IN denotes in
T1209 104-115 NN denotes development
T1210 115-116 . denotes .
T1211 116-225 sentence denotes Therefore, we developed a mouse model of Alzheimer-type amyloid that expresses a controllable APP transgene.
T1212 117-126 RB denotes Therefore
T1214 126-128 , denotes ,
T1215 128-130 PRP denotes we
T1213 131-140 VBD denotes developed
T1216 141-142 DT denotes a
T1218 143-148 NN denotes mouse
T1217 149-154 NN denotes model
T1219 155-157 IN denotes of
T1220 158-167 NNP denotes Alzheimer
T1222 167-168 HYPH denotes -
T1221 168-172 NN denotes type
T1223 173-180 NN denotes amyloid
T1224 181-185 WDT denotes that
T1225 186-195 VBZ denotes expresses
T1226 196-197 DT denotes a
T1228 198-210 JJ denotes controllable
T1229 211-214 NN denotes APP
T1227 215-224 NN denotes transgene
T1230 224-225 . denotes .
T1232 226-230 DT denotes This
T1233 231-237 NN denotes system
T1235 237-239 , denotes ,
T1236 239-247 RB denotes commonly
T1237 248-253 VBN denotes known
T1238 254-256 IN denotes as
R785 T1191 T1190 pobj patients,in
R787 T1194 T1195 advmod However,are
R788 T1196 T1195 punct ", ",are
R789 T1197 T1198 det the,inhibitors
R790 T1198 T1195 nsubj inhibitors,are
R791 T1199 T1198 amod chemical,inhibitors
R792 T1200 T1198 compound secretase,inhibitors
R793 T1201 T1202 advmod most,likely
R794 T1202 T1198 amod likely,inhibitors
R795 T1203 T1204 aux to,reach
R796 T1204 T1202 xcomp reach,likely
R797 T1205 T1206 amod human,trials
R798 T1206 T1204 dobj trials,reach
R799 T1207 T1195 advmod still,are
R800 T1208 T1195 prep in,are
R801 T1209 T1208 pobj development,in
R802 T1210 T1195 punct .,are
R803 T1212 T1213 advmod Therefore,developed
R804 T1214 T1213 punct ", ",developed
R805 T1215 T1213 nsubj we,developed
R806 T1216 T1217 det a,model
R807 T1217 T1213 dobj model,developed
R808 T1218 T1217 compound mouse,model
R809 T1219 T1217 prep of,model
R810 T1220 T1221 compound Alzheimer,type
R811 T1221 T1223 compound type,amyloid
R812 T1222 T1221 punct -,type
R813 T1223 T1219 pobj amyloid,of
R814 T1224 T1225 dep that,expresses
R815 T1225 T1223 relcl expresses,amyloid
R816 T1226 T1227 det a,transgene
R817 T1227 T1225 dobj transgene,expresses
R818 T1228 T1227 amod controllable,transgene
R819 T1229 T1227 compound APP,transgene
R820 T1230 T1213 punct .,developed
R821 T1232 T1233 det This,system
R823 T1235 T1233 punct ", ",system
R824 T1236 T1237 advmod commonly,known
R825 T1237 T1233 acl known,system
R826 T1238 T1237 prep as,known